eligibility_summary
Eligibility: Phase 1a—advanced UC, HNSCC, breast, cervical, ovarian, NSCLC, or pancreatic cancer, ≥1 prior regimen, no effective options. Phase 1b—UC, TNBC, or cervical cancer after ≥1 regimen with no appropriate standard therapy (or refused). Requires RECIST 1.1 measurable disease, ECOG 0–1, adequate hematologic, liver, renal function. Excludes active/uncontrolled CNS mets, major CV disease, other malignancy <3y, therapy within 5 half-lives/14d, P‑gp/strong CYP3A drugs <14d, or systemic antibiotics for active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: ADRX-0706, an antibody–drug conjugate (ADC, targeted cytotoxic therapy) directed at Nectin-4 (PVRL4). Mechanism: the monoclonal antibody binds Nectin-4 on tumor-cell surfaces, is internalized, and releases an intracellular cytotoxic payload to kill the cancer cell, Fc-mediated effector functions may also contribute. Indications in this study: dose escalation in select advanced solid tumors, dose expansion in urothelial cancer, triple-negative breast cancer, and cervical cancer. Targets: Nectin‑4–expressing epithelial tumor cells common in these cancers, pathway/cellular target is the Nectin‑4 cell-adhesion molecule with endocytic trafficking enabling payload delivery.